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CHIKUNGUNYA VIRUS GLYCOPROTEINS MEDIATE VIRAL ENTRY AND 
CELLULAR FUSION 
Derek L. Rinchuse, M.S. 
University of Pittsburgh, 2012 
 
The Chikungunya virus (CHIKV) has currently been identified in over 40 countries 
and in 2008 was listed as a US National Institute of Allergy and Infectious Diseases (NIAID) 
category C priority pathogen. Outbreaks of the virus have been documented as early as 1779 
and frequent outbreaks have been reported through 1960-2003, most notably in Reunion 
Island, a French overseas department in the Indian Ocean. Out of a total population of 
785,000 in Reunion Island, 300,000 cases were reported including a total of 237 deaths. 
Numerous aspects of the viral life cycle are unknown, with no current vaccine the 
implementation of more research and dissemination of more knowledge is of great public 
health importance. A CHIKV construct was synthesized by Genewiz, containing CHIKV 
structural proteins in pcDNA 3.1.  This construct was used to create CHIKV pseudo-viral 
particles with a luciferase based reporter.  The pseudo-virus was used to survey many cell 
lines for permissivity to infection.  This construct was also used to create 3 other constructs 
containing CHIKV E1, E2, and E3 individually.  These constructs were used individually and 
in combination with each other to create pseudo-viruses for cellular infection.  The cell-cell 
fusion capabilities of the full CHIKV construct along with the individual envelope proteins 
were also tested in a Cre-Lox system. 
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1. INTRODUCTION 
The Chikungunya virus commonly referred to as CHIKV is a word derived from the Kimakonde 
language of Mozambique meaning ‘to walk bent over’ (Sourisseau, M., et al.).  Due to an 
inflammatory response seen in victims joints they often assume a bent posture and find it hard to 
maneuver their limbs (almost to a point of paralysis).  The virus is a positive-sense single 
stranded RNA virus belonging to the genus of Alphavirus and the family of Togaviridae.  
Outbreaks of the virus have been documented as early as 1779 and frequent outbreaks have been 
reported through 1960-2003 in areas of Malaysia, Indonesia, Cambodia, Vietnam, Myanmar, 
Pakistan, Burma, and Thailand.  The most notable outbreak was seen in Reunion Island in France 
through 2005 and 2006 where about one-third of the entire country's population was infected by 
CHIKV.  Out of a total population of 785,000 people 300,000 cases were reported including a 
total of 237 deaths.  CHIKV has currently been documented in over 40 countries and is listed as 
a US National Institute of Allergy and Infectious Diseases (NIAID) category C priority 
pathogen.  (Sourisseau, M., et al.) 
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1.1  EPIDEMIOLOGY 
CHIKV had its first recorded epidemic in Tanzania in 1952 and was first isolated after this event 
(Her, Z., et al).  Many infections have been reported in Vietnam, Burma, Cambodia, Sri Lanka 
and the Philippines.  Some sequencing data suggests that CHIKV originated in Africa and was 
introduced later to many parts of Asia. Many epidemics of CHIKV were also reported in the 
Philippines between the 1950’s and 1960’s, and many outbreaks were reported in India from the 
1990’s to early 2000’s (Sudeep, A.B et al).  One of these outbreaks was seen in Kinshasa 
between 1999-2000 infecting an estimated 50,000 people. The virus was first isolated in 1963 in 
Calcutta, India (Pialoux et al).  Since 2005 it is estimated that there have been more than 
1,400,000 cases in India.  Between 2005 and 2006 it has been estimated that there are 
approximately 1,400,000 to 6,500,000 cases in India (Sourisseau, M., et al.). Other cases have 
been reported in Germany, Norway, China, Italy, and Switzerland.   Many of the large epidemics 
seen are typically centered on seasons with heavy rain.  Seasons with large amounts of rain 
increase the density of the vector population; therefore, increasing human contact with the 
vector.  Malaysia was hit with its first CHIKV epidemic in 1998, which was brought in from 
migrant workers.  Many epidemics of CHIKV have also been plagued by infections with not 
only CHIKV, but also with yellow fever, dengue virus, and Plasmodium falciparum.   
 
The scariest epidemic of CHIKV was seen in Reunion Island in 2006 with 300,000 cases 
reported in a population just under 800,000 (Bonn, D.) (Schuffenecker, I., et al).  The rapid 
spreading of the virus to so many people was associated with a change in mosquito species from 
Aedes aegypti to Aedes albopictus due to an alanine to valine at position 226 mutation of the E1 
envelope protein of the virus (D'Ortenzio, E., et al). It has been speculated by some that the virus 
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could have been spread by other means than a mosquito vector, such as a respiratory spreading 
(although no data has been shown that the virus actively infects lung cells to date).  A possible 
respiratory infection may also explain the over 200 deaths associated with the Reunion Island 
outbreak (which is typically non-fatal). Another proposed theory on the Reunion Island outbreak 
is that the virus entered the island into a population with no immunity.  The highly sensitive 
population was infected at an increasingly high rate due to the large abundance of the Ae. 
albopictus mosquito (Sourisseau, M., et al.).  Interestingly during the same outbreak of CHIKV 
out of 35 pregnant women who were infected during delivery, 30 of these women delivered an 
infected child.  (Pialoux et al).  Due to this recent switch in mosquito species to Ae. albopictus 
many reports of infection have been documented in the USA, Europe, and numerous South East 
Asian countries (Gibney, K.B., et al). This included a recent outbreak in 2007 in Kerala, India 
that infected 70,731 individuals, which was directly associated with the A226V mutation 
(Kumar, N.P., et al).  These cases have mainly been linked to infected individuals who either 
travel or work internationally.  (Lo Presti, A., et al) (Petersen, L.R et al) (Santhosh, S.R., et al) 
(Schuffenecker, I., et al) (Sudeep, A.B et al) (Sourisseau, M., et al.) 
1.2 TRANSMISSION 
CHIKV is transmitted by the Aedes species of mosquitoes. The virus follows two forms of 
transmission, an urban cycle and a sylvatic cycle.  The urban cycle uses humans as a main 
reservoir.  In this cycle the mosquito bites a human infected with the Chikungunya virus, which 
is then passed on to another human when they are bitten by the infected mosquito.  In the 
sylvatic cycle animals including; monkeys, rodents, birds, and a few unidentified vertebrates 
 4 
serve as reservoirs while the Aedes mosquitoes still act as vectors and transmit the disease to 
humans. This cycle works similarly to the urban cycle, but instead of the mosquito becoming 
infected by a human reservoir, they are infected by an animal reservoir. The infected mosquito 
can then infect a human with the virus, which can reinitiate the urban cycle or continue the 
sylvatic cycle. (Petersen, L.R et al) (Singh, S.K.)  
 
Even though some non-human vertebrates have been shown to carry the virus, humans 
have been the only documented reservoirs to be present during epidemics.  In fact the sylvatic 
cycle of the virus has not yet been reported in Asia, but only Africa. (Gibney, K.B., et al.,)   
 
The main mosquito vector during the early outbreaks of CHIKV was the Ae. aegypti. 
During the Reunion Island outbreak a mutation was seen changing this to the Ae. albopictus 
mosquito.  The A226V mutation not only caused increased fitness in Ae. albopictus, but also 
caused an increase in transmissibility and a reduction of infectivity in Ae. aegypt.  The Ae. 
albopictus mosquito has seen a recent expansion in territory from South East Asia into 
Madagascar, the Indian Ocean, Africa, and temperate areas of Southern Europe and the U.S.A. 
(Jain, M et al.) (Kononchik, J.P., et al.) 
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1.3 VIRAL GENOME AND STRUCTURE 
The Chikungunya virus belongs to the genus of Alphavirus in the family of Togaviridae. It has a 
single stranded RNA genome approximately 11.8 Kb in length. As with other Alphaviruses 
CHIKV is very small having an icosahedral shape, 60-70 nm capsid, and a phospholipid 
envelope (Gibney, K.B., et al.) (Leung, J.Y., et al.). It is currently proposed that CHIKV follows 
similar methods of replication as other Alphaviruses. 
 
1.3.1 STRUCTURE 
Chikungunya virus gains its envelope from the host after viral shedding. The envelope is a 
phospholipid biliayer mainly comprised of the lipids contained within the hosts own plasma 
Figure 1. A depiction of the CHIKV replication. The urban cycle (left) shows the infection cycle from human, to 
mosquito, and back to human.  The sylvatic cycle (right) shows the infection cycle from a non-human mammal, to 
mosquito, and then to human. 
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membrane. With CHIKV seeming to be very closely related with other Alphavirus structures it is 
most probable that the thickness of the virion envelope is similar to the Sindbis virus (SIN).   
SINs envelope has a thickness of approximately 4.8 nm and is centered at a radius of 23.2 nm 
(Strauss, J.H. et al.).   It was proposed that CHIKV followed a similar structure of other 
Alphaviruses with 240 copies of E1 (approximately 63kDa in SIN) and E2 (approximately 59 
kDa in SIN) embedded into the outer membrane (Anthony, R.P., and  D. Brown ).  This was later 
confirmed by x-ray crystallography (Voss, J.E., et al.) showing E1 and E2 forming 80 spikes 
arranged in a T = 4 icosahedral structure. E1 and E2 are anchored in the membrane by 
membrane-spanning anchors found in their C-terminus.  Cross-linking studies done on other 
Alphaviruses suggest that the envelope trimers are held together by E1-E1 binding.  The trimer 
spikes stalk is formed by an anti-clockwise twisting of the three E1-E2 heterodimers.  The tip of 
each heterodimer has an E1 and E2 separation, and the spikes extend approximately 34 nm from 
the envelope (giving the virion its total diameter). (Strauss, J.H. et al.) (Anthony, R.P., and  D. 
Brown ) (Kononchik, J.P., et al.) 
1.3.2 GENOME AND REPLICATION 
CHIKV contains two open reading frames (ORFs), a 5’ cap structure and a 3’ poly A tail.  The 
first ORF is responsible for producing the non-structural proteins with two polyprotein 
precursors of nsP1, nsP2, nsP3, and nsP4.  The read through codon is responsible for making a 
major product of nsP123, and a minor product of nsP1234.  The second ORF is responsible for 
producing the viral structural proteins: the capsid proteins; envelope glycoproteins E1, E2, and 
E3 and an additional protein, 6K. The viral envelope protein E3 appears to protect E1 from 
fusogenic conformational changes during egress, and is a secreted protein.  Envelope protein E2 
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is postulated to be responsible for viral attachment.  E1 may be responsible for promoting the 
release of the viral nucleocapsid (Kuo, S.C., et al). Two-hundred-and-forty copies of E1 and E2 
form  heterodimers that are imbedded into the CHIKV viral membrane (Tsetsarkin, K.A. et al).  
Together these glycoproteins would appear to be the main drivers in attachment to the host cell. 
The E2 and E1 heterodimers have been shown to cause viral membrane fusion by a cholesterol 
dependent mechanism (Kuo, S.C., et al).  The 6K (approximately 6000 Da) protein appears to 
potentially have multiple roles in glycoprotein processing, cell permeabilization, and viral 
budding (Jose, J., et al.,).  (Kuo, S.C., et al) (Niyas, K.P., et al) (Singh, S.K.) (Kononchik, J.P., et 
al.) 
 
 
Figure 2. Rendition of the CHIKV Genome.   
1.4 VIRAL LIFE CYCLE 
The life cycle of the CHIKV virus is currently still being researched.  It is proposed that 
CHIKV follows a similar life cycle to other Alphavirus and Togaviridae such as Sindbis virus, 
Semliki Forest virus, and Ross river virus (Singh, S.K.) (Sourisseau, M., et al.).  The life cycle 
Figure 2. Rendition of the CHIKV Genome. The genome consists of two open reading frames, creating the non-
structural protein 1-4 (nsP1, nsP2, nsP3, and nsP4) and the structural protein (C-Capsid, Envelope proteins 1-3, and 
glycoprotein 6K).  The virus genome also has a 5’cap and 3’ poly A tail. 
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starts by the virus attaching to the host cell by an unknown receptor.  It is currently proposed that 
virus uses the E2 viral receptor for attachment to the host although the actual host binding 
receptor is unknown.  With the broad spectrum of virally infectable cell lines, it would appear the 
receptor is something common between a multitude of cell lines (Sourisseau, M., et al.). The 
virus is then taken up by some form of mediated endocytosis (most likely clathrin coated) 
(Liljestrom, P., et al.).  A low endosomal pH would then expose a fusion peptide to fuse the viral 
envelope with the host membrane and release the nucleocapsid into the cells cytoplasm.  The 
nsP123 and nsP1-4 would be translated from the viral genome, then nsP123 would bring 
nsP1234 along with other host factors to produce a replication complex (RC).  The RC would 
then produce full length negative strand RNA.  When nsP123 has a sufficient concentration it 
would be cleaved into nsP1, nsP2, nsP3, and nsP4, and, alongside host proteins, act as a plus 
strand replicase to produce a 26s RNA strand.  A promoter would then initiate the transcription 
of 26s sub-genomic positive RNA.  The structural polyprotein then would most likely be cleaved 
into the individual structural proteins.  A nucleocapsid protein would be produced and other 
glycoproteins would be sent to the ER for processing.  The E2 and E3 proteins appear to be 
processed as a single polypeptide until cleaved by a furin-like protease, and have been shown to 
be semi-unstable alone at low pH (Jose, J., et al.,). The E2 precursor is commonly known as PE2 
or p62. The E2/E3 polyprotein is critical for preventing E1 from assuming a fusogenic 
conformation during low pH stages in egress. The preprocessed form of E3 and E2 is commonly 
referred to as the p62 structure (Voss, J.E., et al). The complex of proteins would then move 
through the Golgi and the virion would start to be assembled in the cytoplasm.  The virus would 
then bud through the host membrane.  E1 and E2 also appear to form a bilayer consisting of 
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about 80 E1/E2 trimers. (Singh, S.K.) (Tang, B.L et al) (Leung Y et al) (Liljestrom, P., et al.) 
(Kielian, M., et al.) (Jose, J., et al.,) 
  
 
 
 
1.5  VIRAL PATHOGENESIS 
The pathogenesis of CHIKV occurs with the initial bite of an infected mosquito.  From here 
there would be some form of receptor mediated endocytosis into susceptible cells and production 
of the virus. (Her, Z., et al) A recent mouse model showed that the virus seems to first target and 
Figure 3. Depiction of the CHIKV viral life cycle.  The current method is proposed to follow the same 
mechanisms as that of the togaviruses. Starting with the attachment of the virus to the cell surface, mediated 
endocytosis, release of the viral genome, translation and protein precessing, and finally formation of the viral 
particle and release. 
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replicate in the liver, and then target muscles, joints, and skin.   The virus has been shown to 
actively replicate in lymphoid and myeloid cells, and induce apoptosis in Hela cells and primary 
fibroblasts.  Cholesterol depletion has been shown to lower infectivity by about 65%. (Singh, 
S.K.) The virus mainly seems to target the cells in muscles, especially joints, primarily bone and 
joints associated with connective tissue and skeletal muscles.  CHIKV infection usually clears in 
roughly 1 week, possibly hinting the innate immune system as the main combater.  Since 
CHIKV mainly seems to be an acute disease the chronic aspects have been poorly studied, 
although many people complain of myalgia years after infection. (Her, Z., et al) (Singh, S.K.) 
(Gunn, B.M., et al.) 
1.6 SYMPTOMS AND DIAGNOSIS OF CHIKV INFECTION  
CHIKV infection has a silent incubation period between 2-5 days (Birendra et al) (Pialoux et al), 
and is associated with very high fever over 100oC. Initial symptoms appear to include headache, 
throat discomfort, abdominal pain, and constipation. Encephalitis is not a common symptom 
seen in CHIKV as in other Alphaviruses (Levine B., et al.), and it has not been seen that CHIKV 
is able to actively infect brain cells.  Severe arthralgia is the main symptom with victims having 
mild to very severe joint pain and swelling. The arthralgia appears to be extremely intense 
affecting mainly the ankles, wrists, and phalanges. (Petersen, L.R et al) Arthralgia in infected 
patients seems to be very erratic and crippling. (Pialoux et al).  Currently the mechanism 
associated with joint pain is unknown.  It is speculated that the inflammation could be caused by 
an immune reaction the body uses to combat the virus.  Considering symptoms seem to persist 
even after the clearing of the virus, it would be more probable to assume it is some form of auto 
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immune response. (Pialoux et al)  Some other documented symptoms include chronic arthralgia, 
conjunctivitis, enlarged lymph nodes, and rashes on the body trunk and ear lobes.  One patient 
was also recorded with having facial swelling and itching, which was associated with an oral 
candidiasis associated with CHIKV (Kumar, J.C., et al). Patients displaying symptoms of 
CHIKV are often misdiagnosed with dengue virus, although hemorrhagic fever has been 
reported in Thailand associated with CHIKV infection. Most of the symptoms of CHIKV appear 
to generally resolve themselves within about a week, but joint pain and swelling have been noted 
to last years. (Kuo, S.C., et al) (Petersen, L.R et al) (Sudeep, A.B et al) (Gunn, B.M., et al.) 
 
Currently there are a few diagnostic tests which are used in order to identify a CHIKV 
infected patient.  These include viral isolation, RT-PCR, and ELISA.  The best method of 
detection involves viral isolation, exposing cell lines to samples of the patients blood and 
identifying responses to CHIKV.  In the United States this method of viral isolation; however, 
must be performed in a BSL 3 laboratory, and takes approximately 2 weeks.  RT-PCR is very 
good at detecting virus from the day of infection to day 7, and takes only a few days to perform.  
Serological tests such as ELISA are very easy to perform and can detect IgM about 2 days after 
infection.  ELISA unfortunately tends to show many false positives due to cross reactivity with 
many other arboviruses. (Kumar, J.C., et al) (Pialoux et al) (Sudeep, A.B) 
1.7 TREATMENT AND PREVENTION 
The Chikungunya virus currently has no commercially available vaccine or treatment, leaving 
protection from mosquitoes as the main method in preventing viral spreading (Reiter, P. et al).  
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One of the first direct methods in preventing mosquito contact would be to remove mosquitoes 
from any human inhabited areas (such as cities and homes).  Mosquitoes breed in areas with 
small and/or large pools of stagnant water.  Many people can protect their homes by removing 
these pools of stagnant water from around their yard and neighborhood.  If people are aware of 
areas with high mosquito populations they can wear protective clothing.  Protective clothing 
would be anything having a large amount of skin coverage that is not able to be penetrated by the 
mosquitoe's bite.  A type of insecticide known as pyrethoids can also be used to treat clothing.  
This specific type of insecticide can also be vaporized, which acts as a mosquito repellent.  Other 
commercially available repellents can also be purchased, which include N,N-diethyle-meta-
toluamide (DEET), icardin, and p-menthane-3 8-diol (PMD). (Reiter, P. et al) Many large 
government agencies, such as the CDC in the U.S., track the progression of large mosquito 
populations and attempt to control the mosquitoes migrations into urban areas.  The methods of 
countering the mosquito population can be very labor intensive and expensive.  This is due to the 
constant adaptation of mosquitoes to resist insecticides, and their overall large population.  
(Pialoux et al)  
 
With no currently available vaccine the best practice for treating CHIKV is to treat each 
individual symptom to ensure a patients comfort.  The methods of treatment typically include the 
distribution of analgesics and non-steroidal anti-inflammatory drugs (NSAIDs). A few vaccine 
models are currently being test.  These vaccines include a virus-like particle (VLP) vaccine 
which showed protection in monkeys (Akahata, W., et al) and a DNA vaccine which is designed 
based on CHIKV capsid an envelope sequences (Birendra et al). The US Army Medical 
Research Institute have also been testing a live vaccine based on the CHIKV strain 15561.  The 
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virus was attenuated by passaging through MRC-5 cells, and has started human testing in a phase 
III trial.  Chikungunya infected patients fortunately seem to give a long lasting immune response 
to CHIKV after infection. 
 
New migration patterns of the Ae. Albopictus mosquitoes create a frighteningly real 
threat that the CHIKV virus may be coming to the U.S.  With the high infectivity seen in the 
Reunion Island outbreak the introduction of the virus into the U.S. could be detrimental not only 
to the health of the people, but to the economical status of the areas infected.  With a quickly 
spreading outbreak, the workforce is diminished very quickly leaving no one to perform the daily 
jobs that keep us going every day. As an example imagine there was a very large outbreak of 
CHIKV leaving a large area unable to work. It is possible the people in this area could work for a 
large power company. With no one to run the machinery in the power plant, energy could not be 
supplied to local business.  With the new A226V mutation the virus could spread very rapidly 
and incapacitate an extremely large workforce for weeks to months.  This would drastically 
impact the economy, and unfortunately with unknown future mutations, may become a more 
deadly infection.  This would highlight the need to an increase in understanding of the virus and 
implementing more research in vaccine and treatment developments. 
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2.0       AIM 1 - INVESTIGATING THE CELLULAR TROPISM OF CHIKV USING
 PSEUDO-TYPED VIRUS 
2.1 AIM 1.1 - CREATING A CHIKUNGUNYA PSEUDO-VIRUS SYSTEM 
Currently, in the U.S., the Chikungunya virus is studied at a BSL 3 safety level.  With the 
confines of working in a BSL 2+ laboratory it was imperative that we find a suitable system to 
study CHIKV under these conditions.  A pseudo-viral system was used by creating a 
Chikungunya virus lacking its non-structural proteins, and keeping its structural proteins. 
Pseudo-viruses have been shown to be extremely useful in the fields of scientific advancements 
and previous reports showed the early African strain 37997 as being a good candidate for 
pseudo-viral use (Salvador et al), we chose this strain as our template 
(http://www.ncbi.nlm.nih.gov/nuccore/AY726732.1).  The Chikungunya virus construct was 
crafted using Vector NTI and sent to the company Genewiz for synthesis.  The construct 
contained the CHIKV viral structural proteins from the capsid to the E1 protein, inside the 
multiple cloning site (MCS) of pcDNA3.1 expression plasmid (Figure 4) .   
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Figure 4. Synthesized CHIKV 37997 expression plasmid. CHIKV structural proteins were placed inside the 
multiple cloning site of pcDNA 3.1, which were cloned by Genewiz.  The plasmid contains CHIKV structural 
proteins core, E3, E2, E1, and 6K. 
 
2.2 AIM 1.2  - CHIKUNGUNYA PSEUDO-VIRUS 
In order to assess the cellular tropism of the virus a stable pseudo-virus was created using the 
plasmid created by Genewiz (pCHIKV 37997).  A transfection was performed on 293T LentiX 
cells containing the plasmids pTrip Luciferase, ∆R8.2 (http://www.addgene.org/12263/), and 
pCHIKV 37997. This would create a viral particle that has a HIV core structure (from the ∆R8.2 
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construct), expressing CHIKV viral envelope proteins (from the pCHIKV 37997 construct), and 
is able to be detected by the internalized luciferase construct (pTrip Luciferase).   
2.2.1 AIM 1.2.1 - CELLULAR TRANSFECTION 
In order to perform the transfection 293T LenX cells were first grown in DMEM (Dulbecco's 
Modified Eagles Medium) complete media containing 10% fetal bovine serum (FBS), 1% 
Penicillin-Streptomycin, and 1% non-essential amino acids. Cells were grown in a 10cm dish to 
confluence of about 70%. A transfection mixture was then made by placing pCHIKV 37997, 
pTrip Luciferase, and ∆R8.2 in Optimem at a 1:1 ratio (Figure 5).  Polyethylenimine (PEI) was 
added to the Optimem at a concentration double to the amount of plasmid DNA added. For 
example if there was 5ug of DNA added, then 10ug of PEI was added. The addition of PEI 
positively charges the added plasmid DNA and allows it to better target the anionic surface of the 
cells for better uptake. The Optimem mixture was allowed to set for about 30 minutes. While the 
Optimem was setting pre-warmed DMEM containing only 10% FBS was added to the 293T 
LenX cells, after the removal of the old complete DMEM.  The Optimem mixture containing 
DNA and PEI was added dropwise to the 293T cells.  This transfection mixture was allowed to 
sit on the cells for 5 hours.  After 5 hours the media was changed to pre-warmed complete 
DMEM. Once 24 hours passed the old DMEM was removed and replaced with fresh complete 
DMEM.  The pseudo-virus was then harvested after 48 hours.   
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2.2.2 AIM 1.2.2 - HARVESTING PSEUDO-VIRUS 
To harvest the virus the supernatant was removed and spun in a centrifuge for 15000xg for 5 
minutes.  This ensures that most of the dead cells and/or cellular debris are removed from the 
viral containing media.  After centrifugation the media was removed from the cell pellet and run 
through a 0.45 µm filter syringe into a clean microfuge tube.  Virus that was not used for 
infection immediately was aliquoted into 2mL microfuge tubes and placed at a -80o freezer.  
 
Figure 5. Visual representation of pseudo-viral transfection method.  Plasmids ∆R8.2, pTrip Luciferase, and 
pCHIKV 37997, were co transfected into 293T LentiX cells in order to produce a HIV based pseudo-virus 
expressing CHIKV envelope glycoprtoeins. 
 
 
2.2.3 AIM 1.2.3 - PSEUDO-VIRAL INFECTION 
In order to ensure the virus was actively able to infect cells a trial infection was performed on 
293T cells.  293T cells were plated in a 48 well plate to a confluencey of 70%.  The freshly 
collected CHIKV pseudo-virus, along with a VSV-G positive control, pcDNA3.1 blank, and a 
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pseudo-virus containing only pTrip-Luciferase and pCHIKV 37997 were used to infect the 293T 
cells.  The pseudo-virus containing only pTrip Luciferase and pCHIKV 37997 was used as a 
control, considering the pCHIKV 37997 construct still contained the capsid proteins it needed to 
be verified that the capsid wasn't creating viral-like particles containing an encased pTrip-
Luciferase plasmid.  To infect the cells the collected virus was added to the cells after the 
removal of the media.  Before addition of virus the chemical polybrene was added to the virus at 
a concentration of 4 ug/uL in order to increase the viral infectivity.   
 
 
Figure 6. Graphical Representation of Pseudo-Viral Infection and Cellular Lysis to Luciferase Reading.  Cells 
were initially infected with CHIKV pseudo-virus.  After 48 hours a 1x passive lysis buffer was added to the cells to 
induce lysis.  Cells were shaken on an electronic shaker for approximately 15 minutes with the lysis buffer. After 15 
minutes the cell lysate was placed in a luminometer white plate and read in a luminometer.   
LARII Luminometer
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Figure 7. Initial CHIKV Pseudo-viral Infection. CHIKV pseudo-virus was made in 293T cells by transfecting the 
cells with the synthesized CHIKV construct, pTrip Luciferase, and ΔR8.2. Pseudo-virus was used to infect an initial 
round of 293T cells. A positive control was made using VSV-G instead of CHIKV.  Two negative controls were 
made,  one containing pcDNA3.1  and the other containing only the CHIKV construct and pTripLuciferase. 
 
The pseudo-viral infection was allowed to go for 5 hours on the cells and was then 
replaced with pre-warmed fresh complete DMEM media.  The cells were then allowed to 
incubate for 48 hours.  After 48 hours the cells were lysed with 1x passive lysis buffer.  After 
lysis a luciferase activating reagent (LAR) was added to the lysates and the lysates were read on 
a luminometer (Figure 6).  The readings suggested that the CHIKV pseudo-virus was in fact 
infectious to 293T cells compared the positive and negative controls.  This data provided proof 
that this pseudo-virus could be used in the subsequent screening assays (Figure 7).  
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2.3 AIM 1.3 - CHIKV PSEUDO-VIRAL INFECTIONS ON MULTIPLE CELL LINES 
To this date the amount of survey data present on the Chikungunya virus seems very limited.  
Knowing which cells lines the virus actively infects could lead to a better understanding of the 
human pathogenesis, and could lead to the use of certain cells lines for future studies.  
 
In order to evaluate which cells lines could be infected CHIKV pseudo-virus was created, 
along with the VSV-G positive control virus, and the two negative controls containing either 
pcDNA 3.1 or pCHIKV37997 and pTrip Luciferase.  These pseudo-viruses were created in the 
same fashion as in AIM 1.2.  Human epithelial kidney 293T (HEK 293T) cells (originally 
derived from HEK 293 cells by the addition of SV40 large T-antigen), Huh 7.5.1 hepatoma cells 
(derived from Huh 7.5 cells lacking RIG-1), human brain microvascular endothelial cells 
(HBMECs) (isolated from cortical tissue, highly specialized and responsible for blood-brain 
barrier formation), Verda Reno (VERO) African green monkey kidney cells, A549 
adenocarcinomic human alveolar basal epithelial cells (cultured from the removal of cancerous 
lung tissue), Caco-2 human epithelial colorectal adenocarcinoma cells (cultured cells resemble 
enterocytes lining the small intestine),  C8 mouse macrophage cells, Jurkat T lymphocyte cells 
(immortalized IL-2 producing T-cell derived from a 14 year old boy), H9 T-cells (derivative of 
Hut 78 T-cells derived from peripheral blood of a Sezary syndrome patient), CEM-SS T4-
lyphoblast cells, and C6/36 mosquito cells (derived from Ae.Albopictus mosquito larval tissue) 
were all of the cell types infected with the CHIKV pseudo-virus.  The adherent cell lines were 
infected in the same manner as the 293T cells.  Suspension cell lines (C8, Jurkat, H9, and CEM-
SS) were infected by spin infection.   
 21 
2.3.1 AIM 1.3.1 - Pseudo-Viral Spin Infection 
Before cells were infected a centrifuge was allowed to heat to 33oC.  After the centrifuge was 
allowed to heat cells were suspension cells were pelleted down and resuspended in viral 
containing media. The  suspension cells containing virus were placed in 24-well plates and 
allowed to spin at low speeds (about 2000xg) for an hour. After 1 hour the suspension cells were 
pelleted down in clean microfuge tubes and re-suspended in fresh complete media.  These were 
then transferred back into the appropriate wells.  After infection the cells were allowed to grow 
for 48 hours.  After 48 hours the cells were pelleted down and lysed with 1x passive lysis buffer 
(as done before with adherent cells) and read in a luminometer (Figure 6). 
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Table 1. CHIKV Pseudo-viral Infection Survey of Multiple Cell Lines.  
 
 
2.3.2 AIM 1.3.2 - PSEUDO-VIRAL INFECTION RESULTS 
After adherent and suspension cells had been read on the luminometer, luciferase data was 
compiled. Cell lines with readings under 200 relative light units (RLUs), were deemed not 
infectious in comparison with the blank reading.  Readings over 1,000 RLUs were deemed as 
infectious (Table 1).  In order to accurately interpret the results, all positive and negative 
readings were also displayed graphically (Figures 8, 9, & 10). 
Using the same pseudo-typing method to create pseudo-virus in figure 1, CHIKV pseudo-virus was used to infect 
numerous cell lines. RLUs are a depiction of the averages from 3 individual trials in 3 independent experiments * 
Under 200 RLUs ,  ** 1000-10,000 RLUs,  *** 10,001-20,000 RLUs, **** 50,000 – 1,000,000  RLUs,  *****  
1,000,001 – 2,000,000 RLUs 
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Figure 8 A-F. Positive Results of CHIKV Pseudo-viral Infected Cells with Positive and Negative Controls. 
Cell lines from table 1 that were shown to be infectable are shown here displayed with the appropriate controls as in 
figure 6.  Each individual  result is the product of 3 individual trials performed in 3 independent experiments. 
 
 
Figure 9 A-C.  Negative Results of CHIKV Pseudo-viral Infected Cells with Positive and Negative Controls. 
Cell lines from Table 1 that were shown to not be infectable are shown here displayed with the appropriate controls 
as in figure 6.  Each individual  result is the product of 3 individual trials performed in 3 independent experiments. 
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Figure 10.  Results from CHIKV Pseudo-Viral Infection of C6/36 cells.  Graphical representation of data 
presented in table 1.  Each individual  result is the product of 3 individual trials performed in 3 independent 
experiments. 
 
 
 
The data shows that all cells except the cells of the T-cell lineage and the C6/36 mosquito 
cell line were infectious to the CHIKV pseudo-virus (Table 1) (Figures 8, 9, & 10). The non-
infectious nature of CHIKV to cells of the T-cell lineage seems consistent with results seen with 
Ross river virus and Semliki forest virus (La Linn, M., et al.) (Strang, B.L., et al.). This data 
C6/36
R
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would seem consistent with some other cellular infections that have been performed (Tang, B.L 
et al) (Sourisseau, M., et al.).  The C6/36 cell line most probably was non-infectious due to the 
mosquito cell line machinery not having the correct proteins to actively produce the luciferase 
protein. This theory is shown to be proven further by the fact that previous data suggests C6/36 
to be highly infectable (Tsetsarkin, K.A. et al). Although not performed in these trials it would be 
possible to test this theory by directly transfecting the luciferase plasmid into C6/36 cells and 
attempt luciferase detection.  Interestingly the HBMEC cell line, a mimic of the human blood 
brain barrier, was highly infectable.  Many infected patients of CHIKV have the complaint of 
acute and chronic migraines, along with dizziness and many other symptoms associated with 
brain trauma.  The infection of the HBMEC cells may be a new lead to the possible infection of 
areas of the human anatomy associated with these symptoms.  Mouse macrophage C8 cells seem 
consitant with other infection data showing CHIKV is able to infect human primary 
macrophages (Sourisseau, M., et al.).  The infection of the A549 alveolar cells may also hint to a 
probable mechanism that was presented in the Reunion Island outbreak.  It was speculated that 
the Reunion Island outbreak spread so fast that another mechanism besides a bite from a vector 
carrier may be associated.  It was presented that a possible air borne mechanism could be the 
causation, although the mechanism of action was unknown.  The lung cell infectivity of the 
A549 cells could provide more evidence to this new mechanism, although one article did show a 
contradiction to A549 infectivity (Sourisseau, M., et al.).   
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3.0  AIM 2 - I NVESTIGATING THE CONTRIBUTION OF INDIVIDUAL VIRAL 
PROTEINS IN CHIKV ENTRY BY TESTING THEIR ABILITY IN PACKAGING 
PSEUDO-VIRUS AND MEDIATING CELL-CELL FUSION 
3.1 AIM 2.1 - DEVELOPMENT OF PLASMIDS EXPRESSING INDIVIDUAL CHIKV 
STRUCTURAL PROTEINS 
After seeing that the CHIKV pseudo-virus was not only able to infect 293T cells, but a number 
of other cells lines, we wanted to look at each individual viral protein and its role in viral entry.  
In order to do this three separate proteins were developed to express the CHIKV envelope 
proteins E1, E2, and E3 individually.   
 
A method of PCR cloning was used in order to manufacture each individual structural 
protein into a pcDNA 4 expression plasmid.  Forward and reverse primers were created (Figure 
12) in order to amplify the structural proteins E1, E2, and E3 from the synthesized CHIKV 
37997 plasmid.  In order to simplify the process the E1 envelope proteins will be discussed in 
detail, but the E2 and E3 envelope proteins were created in the exact same fashion.   
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Figure 11. Simplified Representation of the pCHIKV 37793.  In order to simplify the representation of the steps 
of the PCR process the actual Vector NTI plasmid (left) will be simplified to the other plasmid seen (right).  A 
similar representation will be done for plasmids when specified.  
 
Figure 12. Simplified Drawing of Where Each Individual Primer was Designed to Amplify. Forward and 
reverse primers were designed to amplify the regions of E3, E2, and E1 of the pCHIKV37997 plasmid.  E3 and its 
primers are designated by red, E2 and its primers are designated by blue, and E1 and its primers are designated by 
green.   
CHIKV 
37997 in 
pcDNA 3.1
=
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Figure 13. Depiction of the Restriction Digestion of pcDNA4 and the Individual CHIKV Envelopes.  The 
plasmid pcDNA4 and the PCR amplified CHIKV envelopes were digested with restriction enzymes BamH1 and 
Xho1.  The digestion left the pcDNA4 and PCR amplified envelopes with sticky ends due to the enzyme cutting. 
 
 
Figure 14.  Representation of Ligations Performed to Created Plasmids Containing Each Individual 
Envelope.  After pcDNA4 and the amplified CHIKV envelopes had been digested as depicted in Figure 14 the 
products were ligated together with T4 DNA ligase.  The pcDNA4 was ligated with either E3, E2, or E1.   
 
Forward and reverse primers were developed for the E1 structural protein.  A standard 
50µL PCR reaction was set up including the synthesized CHIKV 37997, the forward and reverse 
primers, dNTPs, Phusion polymerase buffer, and Phusion polymerase.  The reaction was placed 
into a PCR machine with an initial denaturing cycle at 98oC for 30s.  A denaturing step of 98oC 
+
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for 10s, an annealing temperature of 55oC for 15s, and an extension cycle of 72oC for 30s per 
1kb was repeated for 35 cycles.  A final extension was performed at 72oC for 10 min.  After the 
PCR reaction was finished the product was run on a 8% agarose gel and gel extracted.  After gel 
extraction the product and pcDNA4 
(http://tools.invitrogen.com/content/sfs/vectors/pcdna4tomychis.pdf) was digested at 40 
overnight with BamH1 and Xho1 (Figure 13).  The next day the two digested products were gel 
extracted and ligated using DNA ligase (Figure 14).  The ligated products were transformed into 
E.Coli and onto LB agar plates with ampicillin.  Colonies were picked from each plate and 
grown in ampicillin LB broth.  After 24 hours of growth the plasmids DNA was extracted from 
the E.Coli using a mini-prep kit (Figure 15). 
 
Figure 15. Initial Steps of the E. Coli Transformation Performed to Amplify the Newly Cloned CHIKV 
Plasmids.  After the individual CHIKV envelope proteins had been ligated into the pcDNA4 they were added to 2 
mL microfuge tube containing DI water,  KCM buffer, and Top10 E. Coli.  The transformation mixture was then 
spread onto an ampicillin resistant LB agar plate. A single colony was plucked from the agar plate after about 24 
hours and this colony was amplified in ampicillin resistant LB broth containing tube.  A miniprep was performed on 
this amplified E. Coli colony using a plasmid mini kit (Omega Bio-Tech #D6943-02).   
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  The purified plasmid DNA was then sent for sequencing to verify the insert had been 
uptaken by the pcDNA 4 vector.  Once the plasmids had been verified by sequencing, the end 
result was 3 individual plasmids expressing E1, E2, and E3 respectively (Figure 16 & 17).  
 
 
Figure 16. Visual breakdown of individual glycoproteins used to create envelope protein plasmids.  The 
glycoproteins E3, E2, and E1 were individually amplified through PCR in order to be cloned into a pcDNA 4 
expression vector.  
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Figure 17. Vector NTI Map of pcDNA4 Plasmids Containing E3, E2, or E1.  After sequencing data returned for 
the newly synthesized CHIKV plasmids, Vector NTI maps were created in order to accurately display a graphical 
representation of all CHIKV plasmids.    
3.2 AIM 2.2 - PSEUDO-VIRAL INFECTIONS OF HEK 293T CELLS BY INDIVIDUAL 
CHIKV GLYCOPROTEIN 
The CHIKV plasmids containing E3, E2, and E1 in pcDNA 4 were used to infect HEK 293T 
cells in order to assess each of their individual roles in viral infection.  Pseudo-virus was made as 
done before using each of the individual envelope proteins, along with a pcDNA 3.1 blank, 
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VSV-G positive control, and a CHIKV pseudo-viral positive control Figure 18).  As before the 
plasmids were transfected into 293T LentiX cells, and harvested 48 hours after transfection.   
 
Figure 18. Display of  Transfection of 293T Cells to Create Pseudo-Virus Containing Either E3, E2, or E1 
Plasmids.  The ∆R8.2, pTrip Luciferase, and either pcDNA4 containing E3, E2, or E1 were transfected into 
293TLenX cells with PEI in order to create pseudo-virus.   
 
The virus was then used to infect 293T cells within a 48-well plate.  After a 5 hour 
infection the media was changed with fresh pre-warmed complete DMEM and the cells were 
allowed to incubate for 48 hours.  The cells were then lysed and a luciferase reading was taken 
(Figure 19). 
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Figure 19. Infection Assay Using Pseudo-Virus Containing Individual CHIKV Envelopes. CHIKV constructs 
containing individualized structural proteins in pcDNA4 were used to create pseudo-virus as depicted in figure 1.  
These constructs were used  singly and in combination with each other.  48hr virus was harvested and used to infect 
293T cells.  The data depicts the average of 3 individual trials in 3 independent experiments.   
 
The data would imply that the CHIKV envelope proteins alone or in combination with 
one another are not enough by themselves to illicit an infection of the pseudo-virus.  Due to some 
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recently published articles verifying the 3D structure or the CHIKV virus and the possible 
mechanism of proteins processing, it could be speculated that the individualized proteins need to 
be transcribed together to function properly. With this in mind, a very strong publication would 
suggest that in order for E2 and E3 to function properly they need to be processed together.   
3.3 AIM 2.3 - ANALYZING THE ROLE OF E3/E2 IN PSEUDO-VIRAL INFECTION 
The E3 and E2 proteins have recently been suggested to be processed together after infection in 
the cell.  This may explain why no infection was detected using each individual protein 
separately to illicit an infection in 293T cells.  To combat this hurdle a new plasmid was 
developed through cloning containing the E3 and E2 proteins together in pcDNA 4.  This 
plasmids was used to create a pseudo-virus containing E3 and E2 together.  This pseudo-virus 
was used to infect 293T cells along with a VSV-G positive control, a CHIKV 37997 positive 
control, and a pcDNA 3.1 positive control. 
 
Figure 20.  Depiction of the pcDNA4 Plasmid Containing the E3-E2 CHIKV Combined Envelopes.  A forward 
primer for E3 and a reverse primer for E2 were used to amplify CHIKV DNA from pCHIKV37997 in order to 
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create a strand of DNA containing E3 and E2 together.  This PCR amplified strand was ligated into pcDNA4 as 
performed previously.   
 
With this being said a new construct containing E3 and E2 together was cloned as 
performed in AIM 2.1 (Figure 20).  This new plasmid was transfecting into 293T cells as done 
above in order to create infectious pseudo-virus. Pseudo-virus was created with the addition of 
the E3-E2 construct individually or in combination with the E1 plasmid. This infectious E3-E2 
pseudo-virus was used to infect 293T cells.  The infection was performed as before and 
luciferase was read in a luminometer (Figure 21).  
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Figure 21.  Pseudo-Viral Infection Assay Performed Using CHIKV Plasmid Containing E3-E2.  Pseudo-virus 
was made using the CHIKV E3-E2 plasmid individually or in combination with CHIKV E1.  The pCHIKV37997 
and VSV-G were used as positive pseudo-viral controls, and pcDNA3.1 was used as a negative control. The data 
depicts the average of 3 individual trials in 3 independent experiments 
 
 The data would seem to suggest that even with the E3 and E2 constructs as a single 
translocational unit, they were not enough to induce a pseudo-viral infection. 
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3.4 AIM 2.4 - ANALYZING THE CHIKV VIRUS ROLE IN CELL-CELL FUSION 
It is known that many viruses cause many cells to fuse into multinucleated cells known as 
syncytia.  In this assay we demonstrate how the expression of CHIKV envelope proteins on the 
cell surface is sufficient in causing cellular fusion.  To accurately measure cellular fusion a Cre-
Lox system is used to evaluate cell-cell fusion.   
 
3.4.1 AIM 2.4.1 - CELL FUSION ASSAY 
293T cells were plated in 24 well plates.  A group of wells were transfected only with the 
plasmids Stop-Luciferase.  This plasmid contains a stop cassette flanked by two lox-p sites 
followed by a luciferase site.  The other wells were transfected with a Cre expression plasmids, 
along with either pCHIKV 37997, VSV-G, or pcDNA3.1. (A control well transfected with Stop-
Luciferase and Cre was also added, along with a Cre only expressing well) (Figure 22).  After a 5 
hour transfection the media was changed to fresh media and the cells were allowed to incubate 
for 24 hours.  After 24 hours the cells were at approximately 100% confluent.  At this point a 
well containing only Stop-Luciferase was mixed with a well containing a viral envelope and Cre.  
These mixtures were placed into a microfuge tube and centrifuged to ensure cell mixing.  The 
pelleted cells were then re-suspended in pre-warmed fresh media and added to wells in a 48-well 
plate.  The cells were allowed to incubate for another 24 hours.  The cells were then lysed and 
read in a luminometer.   
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Figure 22. Cre-LoxP cell-cell fusion expression system.  Individual sets of 293T cells were transfected with either 
Cre + viral envelope, or a stop luciferase construct.  If when the cell lines combine there is a compatible receptor the 
cells will fuse. If fusion is to occur the Cre expressed inside the one cell will remove the loxP sites surrounding the 
stop cassette, allowing the translation of luciferase. 
 
 
Figure 23.  Close Graphical Analysis of the Cre-Lox System Used in Cell-Cell Fusion. Cyclic Recombinase 
(Cre) proteins interaction with the LoxP sites causes their asymmetric sequences to interact forming a loop.  The 
DNA loop contains the stop cassette, which typically would stop the production of luciferase, and removes (cleaves) 
it. The removal of the stop cassette allows for the processing of luciferase, and thus is able to be detected through a 
luminometer.  
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Figure 24.  Cell-Cell Fusion Assay pCHIKV 37997 Construct. Cell-cell fusion assay performed using a Cre-Lox 
detection system.  The synthesized CHIKV construct was transfected in on group of 293T cells along with a Cre 
expression plasmid.  Another set of 293T cells were transfected with StopLuciferase.    A 5 hour transfection was 
allowed to run and cells were left till 100% confluent.  The two batches of 293T cells were then mixed and allowed 
to incubate for 48 hrs.  Cells were lysed and luciferase was then read.  Data is a collection of 3 trials and 3 
independent experiments as fold increase over the blank (Cre transfected cells + pcDNA 3.1). 
 
When the Cre proteins interact with the lox-p sites surrounding the stop cassette the stop 
cassette is removed and the luciferase is able to be actively produced (Figure 23).  Upon analysis 
of the data it would appear that the expression of the CHIKV envelope proteins on the 293T cells 
were sufficient enough to cause cellular fusion as compared to the VSV-G positive control 
(Figure 24).  To specifically pin-point the structural proteins responsible for the cellular fusion 
individual structural proteins were used. 
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3.5 AIM 2.5 - ANALYZING INDIVIDUAL CHIKV GLYCOPROTEINS ROLES IN CELL-
CELL FUSION 
Seeing that the expression of all CHIKV structural proteins caused cellular fusion within 293T 
cells, we examined the role of the individual expression of CHIKV structural proteins in 
correlation with cell-cell fusion.  The fusion assay was performed in the same manner as before, 
with the only difference being the use of the individual CHIKV plasmids expressing E3, E2, and 
E1 individually.   
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Figure 25. Cell-Cell Fusion Assay Using Individual CHIKV Envelopes. A cell-cell fusion assay was performed 
as in figure 4 including the individual CHIKV envelope constructs  transfected singly or in combination with one 
another.  The data is depicted as fold increase of the Cre infected blank.  The data is representative of the average of 
3 trials in 3 independent experiments.  
 
As within the pseudo-viral infection assay, it would also appear that the CHIKV plasmids 
on their own are not sufficient enough to cause cell-cell fusion.  A few questions may be raised 
when looking into this fusion assay.  Many times in order to have properly induced cellular 
fusion a virus needs to have an environment that is fairly acidic.   Without also looking at how a 
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range of pH’s determine the ability of CHIKV to induce cellular fusion, it may be very difficult 
to speculate upon the results. 
3.6 AIM 2.6 - PH DEPENDENT CELL-CELL FUSION USING CHIKV STRUCTURAL 
GLYCOPROTEINS 
A multitude of citric acid buffers were created consisting of various pHs.  The pHs were as 
follows: 7.0, 6.5, 6.0, 5.9, 5.8, 5.7, 5.6, 5.5, 5.4, and 5.0.  A cellular fusion assay was performed 
almost exactly as done previously.  The 293T cells were transfected as before and the cells were 
mixed and distributed to the 48-well plates as done earlier.  After the cells were allowed to 
incubate in the 48-well plates for 24 hours the individual citric acid buffers were added and left 
to incubate on the cells for 5 minutes.  After 5 minutes the buffer was removed and the cells were 
allowed to recover and incubate for another 24 hours.  Unfortunately, after many trials and 
different buffer time courses most of the cells had died the subsequent day and were unable to be 
read for fusion. Currently more buffers are being researched to attempt this trial. 
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4.0  DISUSSION AND CONCLUSION 
Seeing the detrimental results at Reunion Island and the potential for the Chikungunya virus to 
cause an outbreak in the United States, it appears now more than ever more research is needed to 
combat this virus.  Our current research has shown that the Chikungunya virus was infectious to 
numerous human cells.  Interestingly the virus was shown to infect a blood brain barrier mimic, 
HBMECs.  As to our knowledge there has not been an account previously published showing a 
correlation to patient symptoms associated with brain infection (such as headache, dizziness, 
etc).  The infection of the blood brain barrier (although not showing an infection of actual brain 
cells) could provide more information on the possibility of CHIKV in causing infectivity in the 
brain.  A topic also interesting to note is the infection of the A549 alveolar cells.  A previous 
author has suggested that another mechanism of infection could be possible.  This was 
speculated with the high rate of infection seen in the Reunion Island outbreak.  They proposed 
that a possible unknown mechanism of transmission could be possible, such as one of the 
respiratory tract.  Most other data of CHIKV epidemics would most likely show this method as 
false, but it is very interesting to note the high rate of infection in lung cells seen in the pseudo-
viral infection.  Humans have been noted as the main reservoirs for the CHIKV virus, although 
many other animals have been noted to be reservoirs besides humans.  The infection of the 
VERO African green monkey cells would show that other species of mammals are in fact able to 
be infected besides humans.  This would provide more evidence on the basis that monkeys can 
 45 
be reservoirs for CHIKV.  The only human cell line that seemed immune from CHIKV infection 
that was tested would appear to be T-cells.   
 
After testing the CHIKV pseudo-virus on numerous cell lines, we wanted to analyze the 
individual CHIKV glycoproteins.  The pseudo-viral infections using individualized glycoproteins 
suggested that the individualized proteins themselves were not sufficient in causing pseudo-viral 
infection.  Looking into recent studies, it would appear the complex processing of the CHIKV 
proteins (specifically the E3 and E2 proteins) could be causing the lack of infection.  Noting this, 
a new construct was created containing E3 and E2 together.  This plasmid also failed to illicit a 
luciferase response, even with the co-transfection of E1.  With the pseudo-virus containing all 
structural proteins being able to infect the cells, it would appear we are missing a key point with 
the individualized proteins.  It is quite possible that the mechanism of protein processing for 
CHIKV needs all key proteins together in order to be processed.  We examine this further by 
analyzing the role of CHIKV and its individualized glycoproteins in cell-cell fusion. 
 
The full CHIKV 37997 construct was able to cause cellular fusion in 293T cells.  As seen 
in the pseudo-viral infection assay, using individualized glycoproteins was not sufficient in 
causing cellular fusion.  The complex processing and distribution of the glycoproteins on the 
cellular surface most likely is the key to the negative results seen in this assay.  However, it is 
also possible there is a pH dependent mechanism negating the fusion process.  To ensure pH was 
not playing a key role in the mechanism of cellar fusion, multiple citric acid buffers were used 
during the fusion assay.  The buffers used unfortunately caused a high amount of cell death, and 
no luciferase readings were able to be read.  This experiment is currently being tweaked in order 
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to limit the amount of cellular death.  Looking at the data of the full CHIKV construct being 
compared to the VSV-G positive control, it would appear the CHIKV is in fact giving a fairly 
good reading of cellular fusion.  This would suggest the data, although not tested to its maximum 
potential, is fairly reasonable.  Individualized CHIKV glycoproteins were also analyzed by 
cellular fusion.  
 
Each individual CHIKV envelope protein was tested for cellular fusion capabilities.  The 
data would suggest that these glycoproteins individually or in unison with one another do not 
seem to grant cellular fusion.  This data would also coincide with the data received from the 
pseudo-viral infection assay, showing that without the full construct the individualized plasmids 
do not seem to show a response.  Most probably with the same reasoning in mind as before, the 
processing and expression of the CHIKV glycoproteins is more complex than placing each 
individual protein in the cell for expression.  It is very probable that the glycoproteins need to be 
in one continuously read strand to be processed and expressed correctly.   
 
From this data it can be seen that CHIKV can infect a multitude of human cells, but 
appears to be unable to do so without the expression of all plasmids in a single construct.  
CHIKV was also able to illicit cellular fusion within 293T cells, but unable to do so when only 
individualized plasmids were expressed.  This data could be very useful in the fact that knowing 
if one individual envelope protein is disrupted, it could possibly make the virus unviable.   
 
Without a proper vaccine or treatment to the Chikungunya virus, now more than ever we 
need more research to combat it.  The new emergence of mutations causing a switch in mosquito 
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vector could mean an epidemic in the United States is not out of our near future.  The research 
presented here gives a solid understanding of the cellular tropism of the virus, and the behaviors 
of individualized glycoproteins in cellular infections and cellular fusion.  In order to investigate 
this issue further, constructs containing the 6K region of CHIKV have been created in order to 
assess its possible association with viral entry and cellular fusion. The E3/E2 construct is also 
further being investigated, to examine its role in cellular fusion.  This data will hopefully inspire 
more research, and/or help other scientist contribute to a global eradication of the Chikungunya 
virus.   
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5.0  MATERIALS AND METHODS 
Transfection 
Transfections were performed using either 293T or 293T LentiX cells.  293T were plated in the 
desired size wells to reach a confluence of approximately 80%.  Once the cells reached the 
desired confluence a transfection media was prepared.  Plasmid DNA was added to Optimem 
solution, along with PEI at a concentration double to the amount of DNA added.  The Optimem 
solution containing DNA and PEI was allowed to incubate at room temperature for 
approximately 30 minutes.  During this incubation time 293T cells had their complete DMEM 
media replaced with  pre-warmed DMEM media containing only 10% FBS.  After the 30 
minute incubation time and the replacement of the media, the Optimem solution containing 
plasmid DNA and PEI was added to the 293T cells slowly drop wise.  The cells were then 
placed back into the incubator for 5 hours.  After 5 hours the media was then changed from 
DMEM containing only 10% FBS to complete DMEM media.  
 
Chikungunya Pseudo-virus 
Chikungunya pseudo-virus was created by transfecting the CHIKV plasmid synthesized by 
Genewiz, ∆R8.2 (HIV Gag-Pol), and pTrip Luciferase.  These were all transfected at 1:1 ratios.  
After the transfection was completed the cells were allowed to incubate for 24 hours.  When 24 
hours was over the DMEM complete media was changed with new complete DMEM media.  At 
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the end of 48 hours the pseudo-virus was harvested.  To harvest the virus the cells and media was 
spun in a centrifuge at 5000 x g for 5 minutes.  After 5 minutes the media was removed from the 
pellet an filtered through a 0.45 µm filter syringe and aliquoted as deemed appropriate and 
frozen or used immediately for infection. (All controls, such as VSV-G and pcDNA 3.1 blank, 
were transfected in the same manner). 
 
Viral Infection 
Once virus had been harvested after 48hrs polybrene was added at a concentration of 4ug/uL. 
Cell media was removed and the virus containing polybrene was then added to the determined 
cells.    Cells were at a concentration of approximately 70% before they were infected.  The virus 
was left to incubate on the cells in the incubator for 5 hours and was then removed.  Fresh pre-
warmed complete media was used to replace the virus media. 
 
Cell-Cell Fusion 
293T cells were plated in 24 well plates.  The cells were allowed to grow to approximately 70% 
confluence.  A transfection was then performed on the cells.  One batch of cells were transfected 
only with the Stop-Luc plasmid.  The other batch of cells were transfected with viral DNA and a 
Cre-expression plasmid.  The next day when the cells were approximately 100% confluent a well 
containing the viral DNA and Cre was mixed with a well containing the Stop-Luc plasmid.  The 
mixed wells were placed in a microfuge tube and spun in a centrifuge at 5000xg for 5 minutes.  
After the cells were centrifuged they were resuspended in fresh DMEM media.  The cells were 
then plated in a 48-well plate to ensure the cells would be 100% confluent the next day.  The 
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cells were allowed to incubate for 48 hours.  The cells were then lysed with 1x passive lysis 
buffer and read on a luminometer after the addition of a luciferase activating reagent.  
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